IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

@article{Mace2018IL6AP,
  title={IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.},
  author={Thomas A. Mace and Reena Shakya and Jason R. Pitarresi and Benjamin J. Swanson and Christopher W McQuinn and Shannon Loftus and Emily Nordquist and Zobeida Cruz-Monserrate and Lianbo Yu and Gregory S Young and Xiaoling Zhong and Teresa A. Zimmers and Michael C. Ostrowski and Thomas Ludwig and Mark A Bloomston and Tanios S. Bekaii-Saab and Gregory B. Lesinski},
  journal={Gut},
  year={2018},
  volume={67 2},
  pages={320-332}
}
OBJECTIVE Limited efficacy of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma (PDAC) has prompted investigation into combination therapy. We hypothesised that interleukin 6 (IL-6) blockade would modulate immunological features of PDAC and enhance the efficacy of anti-programmed death-1-ligand 1 (PD-L1) checkpoint inhibitor therapy. DESIGN Transcription profiles and IL-6 secretion from primary patient-derived pancreatic stellate cells (PSCs) were analyzed via Nanostring and… CONTINUE READING
Highly Cited
This paper has 62 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 17 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

63 Citations

020406020172018
Citations per Year
Semantic Scholar estimates that this publication has 63 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 47 references

A pancreatic tumorspeci fi c biomarker characterized in humans and mice as an immunogenic oncoglycoprotein is ef fi cient in dendritic cell vaccination

  • A Collignon, AT Perles-Barbacaru, S Robert
  • Oncotarget
  • 2015

Similar Papers

Loading similar papers…